Helen L Storr1, Leo Dunkel2, Julia Kowalczyk2, Martin O Savage2, Louise A Metherell2. 1. Barts and the London School of Medicine and DentistryWilliam Harvey Research Institute, Centre for Endocrinology, Queen Mary University of London, London, UK h.l.storr@qmul.ac.uk. 2. Barts and the London School of Medicine and DentistryWilliam Harvey Research Institute, Centre for Endocrinology, Queen Mary University of London, London, UK.
Abstract
OBJECTIVE AND DESIGN: GH insensitivity (GHI) encompasses growth failure, low serum IGF1 and normal/elevated serum GH. By contrast, IGF1 insensitivity results in pre- and postnatal growth failure associated with relatively high IGF1 levels. From 2008 to 2013, 72 patients from 68 families (45M), mean age 7.1 years (0.4-17.0) with short stature (mean height SDS -3.9; range -9.4 to -1.5), were referred for sequencing. METHODS: As a genetics referral centre, we have sequenced appropriate candidate genes (GHR, including its pseudoexon (6Ψ), STAT5B, IGFALS, IGF1, IGF1R, OBSL1, CUL7 and CCDC8) in subjects referred with suspected GHI (n=69) or IGF1 insensitivity (n=3). RESULTS: Mean serum IGF1 SDS was -2.7 (range -0.9 to -8.2) in GHI patients and 2.0, 3.7 and 4.4 in patients with suspected IGF1 insensitivity. Out of 69 GHI patients, 16 (23%) (19% families) had mutations in GH-IGF1 axis genes: homozygous GHR (n=13; 6 6Ψ, two novel IVS5ds+1 G to A) and homozygous IGFALS (n=3; one novel c.1291delT). In the GHI groups, two homozygous OBSL1 mutations were also identified (height SDS -4.9 and -5.7) and two patients had hypomethylation in imprinting control region 1 in 11p15 or mUPD7 consistent with Silver-Russell syndrome (SRS) (height SDS -3.7 and -4.3). A novel heterozygous IGF1R (c.112G>A) mutation was identified in one out of three (33%) IGF1-insensitive subjects. CONCLUSION: Genotyping contributed to the diagnosis of children with suspected GHI and IGF1 insensitivity, particularly in the GHI subjects with low serum IGF1 SDS (<-2.0) and height SDS (<-2.5). Diagnoses with similar phenotypes included SRS and 3-M syndrome. In 71% patients, no diagnosis was defined justifying further genetic investigation.
OBJECTIVE AND DESIGN: GH insensitivity (GHI) encompasses growth failure, low serum IGF1 and normal/elevated serum GH. By contrast, IGF1 insensitivity results in pre- and postnatal growth failure associated with relatively high IGF1 levels. From 2008 to 2013, 72 patients from 68 families (45M), mean age 7.1 years (0.4-17.0) with short stature (mean height SDS -3.9; range -9.4 to -1.5), were referred for sequencing. METHODS: As a genetics referral centre, we have sequenced appropriate candidate genes (GHR, including its pseudoexon (6Ψ), STAT5B, IGFALS, IGF1, IGF1R, OBSL1, CUL7 and CCDC8) in subjects referred with suspected GHI (n=69) or IGF1 insensitivity (n=3). RESULTS: Mean serum IGF1 SDS was -2.7 (range -0.9 to -8.2) in GHI patients and 2.0, 3.7 and 4.4 in patients with suspected IGF1 insensitivity. Out of 69 GHI patients, 16 (23%) (19% families) had mutations in GH-IGF1 axis genes: homozygous GHR (n=13; 6 6Ψ, two novel IVS5ds+1 G to A) and homozygous IGFALS (n=3; one novel c.1291delT). In the GHI groups, two homozygous OBSL1 mutations were also identified (height SDS -4.9 and -5.7) and two patients had hypomethylation in imprinting control region 1 in 11p15 or mUPD7 consistent with Silver-Russell syndrome (SRS) (height SDS -3.7 and -4.3). A novel heterozygous IGF1R (c.112G>A) mutation was identified in one out of three (33%) IGF1-insensitive subjects. CONCLUSION: Genotyping contributed to the diagnosis of children with suspected GHI and IGF1 insensitivity, particularly in the GHI subjects with low serum IGF1 SDS (<-2.0) and height SDS (<-2.5). Diagnoses with similar phenotypes included SRS and 3-M syndrome. In 71% patients, no diagnosis was defined justifying further genetic investigation.
Authors: Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa Journal: Endocr Rev Date: 2019-04-01 Impact factor: 19.871
Authors: Inma Castilla-Cortazar; Julieta Rodríguez De Ita; Gabriel A Aguirre; Joel Rodríguez-Rivera; Mariano García-Magariño; Irene Martín-Estal; Óscar Flores-Caloca; Carlos Diaz-Olachea Journal: Clin Case Rep Date: 2018-01-18
Authors: Jürgen Klammt; David Neumann; Evelien F Gevers; Shayne F Andrew; I David Schwartz; Denise Rockstroh; Roberto Colombo; Marco A Sanchez; Doris Vokurkova; Julia Kowalczyk; Louise A Metherell; Ron G Rosenfeld; Roland Pfäffle; Mehul T Dattani; Andrew Dauber; Vivian Hwa Journal: Nat Commun Date: 2018-05-29 Impact factor: 14.919
Authors: Emily Cottrell; Claudia P Cabrera; Miho Ishida; Sumana Chatterjee; James Greening; Neil Wright; Artur Bossowski; Leo Dunkel; Asma Deeb; Iman Al Basiri; Stephen J Rose; Avril Mason; Susan Bint; Joo Wook Ahn; Vivian Hwa; Louise A Metherell; Gudrun E Moore; Helen L Storr Journal: Eur J Endocrinol Date: 2020-12 Impact factor: 6.664
Authors: Afiya Andrews; Avinaash Maharaj; Emily Cottrell; Sumana Chatterjee; Pratik Shah; Louise Denvir; Katja Dumic; Artur Bossowski; Talat Mushtaq; Rade Vukovic; Mohamed Didi; Nick Shaw; Louise A Metherell; Martin O Savage; Helen L Storr Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 5.958